Inceptionr LLC Purchases New Position in Arrowhead Pharmaceuticals, Inc. $ARWR

Inceptionr LLC purchased a new stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 6,791 shares of the biotechnology company’s stock, valued at approximately $426,000.

Several other hedge funds have also recently bought and sold shares of ARWR. Arrowstreet Capital Limited Partnership boosted its stake in shares of Arrowhead Pharmaceuticals by 3,142.5% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 2,081,689 shares of the biotechnology company’s stock valued at $71,797,000 after purchasing an additional 2,017,489 shares in the last quarter. Norges Bank acquired a new stake in shares of Arrowhead Pharmaceuticals during the 4th quarter worth about $113,159,000. Fred Alger Management LLC increased its position in shares of Arrowhead Pharmaceuticals by 497.4% during the 4th quarter. Fred Alger Management LLC now owns 1,832,997 shares of the biotechnology company’s stock worth $121,693,000 after purchasing an additional 1,526,164 shares in the last quarter. Deerfield Management Company L.P. bought a new position in Arrowhead Pharmaceuticals during the 3rd quarter valued at about $34,249,000. Finally, Vestal Point Capital LP bought a new position in Arrowhead Pharmaceuticals during the 4th quarter valued at about $59,751,000. 62.61% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have weighed in on ARWR. Stifel Nicolaus initiated coverage on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, July 14th. They set a “buy” rating and a $98.00 price objective on the stock. Morgan Stanley lifted their target price on shares of Arrowhead Pharmaceuticals from $100.00 to $120.00 and gave the company an “overweight” rating in a research note on Thursday. Weiss Ratings downgraded Arrowhead Pharmaceuticals from a “hold (c-)” rating to a “sell (d-)” rating in a report on Wednesday, May 20th. Sanford C. Bernstein increased their price target on Arrowhead Pharmaceuticals from $35.00 to $46.00 and gave the stock a “market perform” rating in a research report on Wednesday, May 13th. Finally, Leerink Partners raised their price target on Arrowhead Pharmaceuticals from $61.00 to $72.00 and gave the company a “market perform” rating in a report on Wednesday, June 17th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $93.83.

Insider Transactions at Arrowhead Pharmaceuticals

In other Arrowhead Pharmaceuticals news, Director Hongbo Lu sold 2,970 shares of the company’s stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $76.88, for a total transaction of $228,333.60. Following the transaction, the director owned 52,012 shares of the company’s stock, valued at approximately $3,998,682.56. This represents a 5.40% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 3.60% of the company’s stock.

Arrowhead Pharmaceuticals Stock Performance

ARWR opened at $85.60 on Monday. The company has a current ratio of 6.23, a quick ratio of 6.23 and a debt-to-equity ratio of 1.41. The stock has a market capitalization of $12.06 billion, a PE ratio of -39.81 and a beta of 1.26. Arrowhead Pharmaceuticals, Inc. has a 1-year low of $15.01 and a 1-year high of $95.49. The firm has a 50-day moving average price of $77.94 and a two-hundred day moving average price of $70.02.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its earnings results on Thursday, May 7th. The biotechnology company reported ($0.93) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.10) by $0.17. Arrowhead Pharmaceuticals had a negative net margin of 48.38% and a negative return on equity of 55.09%. The company had revenue of $73.74 million for the quarter, compared to analyst estimates of $73.84 million. During the same period in the prior year, the business earned $2.75 earnings per share. Arrowhead Pharmaceuticals’s quarterly revenue was down 86.4% on a year-over-year basis. As a group, equities analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -3.08 earnings per share for the current fiscal year.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.